8-K: Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

Tivic Health Systems acquires exclusive worldwide license rights from Statera Biopharma to Entolimod, a late-stage Toll-like Receptor 5 (TLR5) agonist, for the treatment of acute radiation syndrome (ARS), diversifying its therapeutics pipeline.

Summary

• Tivic Health Systems, Inc. has acquired exclusive worldwide license rights from Statera Biopharma for Entolimod, a TLR5 agonist, to treat acute radiation syndrome (ARS).
• The agreement includes an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
• This acquisition transforms Tivic into a diversified therapeutics company with both bioelectronic and biologic product candidates.
• The global ARS market is estimated to be valued at USD 5.2 billion in 2024, with a projected annual growth rate of 5% from 2024 to 2031.
• Entolimod has been the subject of over forty animal and human trials with $140 million of prior investment.
• The FDA has granted Fast Track and Orphan Drug designation to Entolimod for ARS treatment and prevention of death following radiation exposure.
• Tivic will initially pay Statera $1,200,000 in equity and $300,000 in cash for the ARS indication.
• Future payments will be royalty and milestone-driven, aligning with the clinical and commercial success of Entolimod and Entalasta.
• Select Statera team members will join Tivic to advance product candidates towards commercialization.
• The transaction includes exclusive rights and options for more than sixty patents and patents pending, associated know-how, and ownership of previously manufactured and tested materials.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the acquisition of a late-stage clinical asset, diversification of the company's pipeline, and potential for significant market growth. The management comments and inclusion of key financial metrics further contribute to the positive sentiment.

Positives

• Tivic gains a late-stage clinical asset with potential for FDA approval within 24 months.
• The acquisition diversifies Tivic's product pipeline and reduces reliance on a single product.
• Entolimod has already undergone significant clinical testing and has received FDA designations.
• The royalty and milestone-driven payment structure aligns incentives and manages Tivic's investment risk.
• The addition of Statera team members brings biopharmaceutical expertise to Tivic.

Risks

• The success of Entolimod is subject to clinical and commercial success.
• Tivic will need to invest additional capital to develop and commercialize Entolimod and other indications.
• Regulatory approval is not guaranteed, and the FDA could require additional testing or data.
• The ARS market may not grow as expected, or Tivic may face competition from other therapies.
• Tivic's ability to successfully integrate the Statera team and technology is uncertain.

Future Outlook

Tivic anticipates advancing Entolimod through the final steps toward a BLA filing and potential FDA approval, with potential expansion into additional indications.

Management Comments

• Jennifer Ernst, Chief Executive Officer of Tivic, stated that the acquisition accelerates Tivic's strategic transformation into a diversified therapeutics company.
• Michael K. Handley, Chief Executive Officer of Statera, believes the agreement has the potential to provide considerable value for both Statera and Tivic shareholders.

Industry Context

The acquisition positions Tivic in the growing immunotherapeutics market, specifically targeting acute radiation syndrome, a market with significant unmet needs and potential for growth.

Comparison to Industry Standards

• The $140 million prior investment in Entolimod suggests a significant level of prior development and validation, comparable to other late-stage immunotherapeutic assets.
• The estimated 5% CAGR for the ARS market aligns with growth projections for other specialized pharmaceutical markets.
• Statera Biopharma is identified by CoherentMI as one of the key market leaders in the global acute radiation syndrome (ARS) market.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to pipeline diversification and market growth.
• Employees: Opportunity for career growth and development within a diversified therapeutics company.
• Patients: Potential access to new therapies for acute radiation syndrome and other indications.
• Suppliers: Potential for increased business opportunities as Tivic expands its product pipeline.
• Creditors: Potential for improved financial stability and creditworthiness of Tivic Health.

Next Steps

• Tivic will advance Entolimod towards a BLA filing and potential FDA approval.
• Tivic will evaluate and potentially exercise options to license additional indications for Entolimod and Entalasta.
• Select Statera team members will join Tivic to support biopharmaceutical capabilities.

Key Dates

Keywords

Tivic Health, Statera Biopharma, Entolimod, TLR5 agonist, Acute Radiation Syndrome, ARS, Immunotherapy, Licensing Agreement, Biopharmaceutical, FDA Approval